Physician Views: CMS guidance on biosimilar reimbursement - what do oncologists and rheumatologists think?

Physician Views: CMS guidance on biosimilar reimbursement - what do oncologists and rheumatologists think?

Code: FW-20150402 | Published: Apr-2015 | Pages: - | FirstWord
Price :
$695.00
USD

* Required Fields

$695.00

Details






Recent FDA approval of the first US biosimilar product has spurred the Centers for Medicare and Medicaid Services (CMS) to publish new guidance relating to biosimilar reimbursement and usage (ViewPoints: New CMS documents should grease the wheels of adoption for biosimilars).

Under Medicare Part B, where products are administered by physicians, the CMS has provided clarification on how biosimilars will be reimbursed: at the average sales price (ASP) of the biosimilar in question plus 6 percent of the ASP of the equivalent branded reference product. This guidance is designed to remove a disincentive for a physician to prescribe a biosimilar. As a result, biosimilars and equivalent branded products will have separate billing codes under Medicare Part B.

Under Part D schemes - for pharmacy administered products - new CMS guidance considers a biosimilar and its equivalent branded reference product to be the same, meaning that a branded product could effectively be replaced with a biosimilar (assuming the plan in question maintains access to two products within a drug class). It has been suggested that this decision implies potential de facto interchangeability status for biosimilars.








To help provide FirstWord Pharma PLUS readers a unique analysis of this development, this week we are polling US-based oncologists and rheumatologists in two separate polls to ascertain initial physician sentiment to the CMS guidance.
In our first poll, focused on Part B reimbursement, we are asking oncologists




- How effective they expect the CMS reimbursement guidance to be in incentivising physicians to use biosimilars
- Whether the decision not to use shared billing codes will have any impact on biosimilar adoption
- How likely they will be to accept payer pressure to use biosimilars outside of the Medicare setting
- What presence they expect biosimilars to have on the US cancer treatment landscape in five years time
- Whether they agree with the view that adoption of biosimilars is necessary to reduce limitations placed by payers on novel cancer therapies

In our second poll, focused on Part D reimbursement, we are asking rheumatologists

- Whether CMS guidance that branded reference biologics and biosimilars "will not be considered as different drugs" will have a positive impact on their adoption of biosimilars
- Their assessment of de-facto interchangeability via CMS guidance
- Their view on interchangeability status for biosimilars in general
- How likely they will be to accept payer pressure to use biosimilars outside of the Medicare setting
- What presence they expect biosimilars to have on the US rheumatology/inflammation treatment landscape in five years time





Report Format

Following are different modes of Licenses.

a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.

b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.

c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.

Quick Help

1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :

a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]

b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]


2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:

a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
d. Paypal


3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.

If you have a more question about our publications please see our FAQs section or contact us now at cs@marketinforesearch.com.

CUSTOMERS WHO VIEWED THIS REPORT ALSO VIEWED

There are no reports matching the selection.

Browse similar reports by category:
Pharmaceuticals & Healthcare
FirstWord

Our Clients